
QMS Medical Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- QMS Medical Allied Services Limited anticipates a 10%-15% annual growth over the next five years, aiming for systematic and sustainable expansion.
- Target to grow the service model to INR100 crores revenue in three years.
- Aim to increase QMS business revenue to INR300 crores+ within three years.
- Growth drivers include devices, point-of-care products, and patient service programs.
- Expansion plans in patient service programs by increasing workforce, geographic reach, and client coverage.
- Focus on introducing diversified and innovative point-of-care product offerings.
- Emphasis on leveraging online platforms, which have already crossed INR10 crores.
- B2B business segment recorded nearly INR50 crores, showing strong potential.
- Commitment to broadening direct-to-consumer presence, addressing chronic care management solutions.
- Collaboration and manufacturing tie-ups for point-of-care products are underway to support growth.
See what QMS Medical management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company planned to raise funds through preferential shares but has not closed this yet.
- Currently, acquisitions like Saarathi Healthcare are being funded through internal accruals and working capital limits.
- No equity funds from preferential allotments or convertible warrants have been received or utilized so far.
- For capex related to expansion and diversification, no additional capex or funding is presently required as enough capital has been pumped in earlier.
- Hospital division funding will come from internal business cash flows; no external fund infusion is required at this moment.
- The company remains open to fundraising but is prioritizing current internal resources to complete ongoing acquisitions and projects before considering new debt or equity fundraisers.
See what QMS Medical management said on order book — free account, 30 seconds.
Capex plans
Yes- Current capital investment: QMS is acquiring a 51% stake in Saarathi Healthcare Private Limited with a payout of around INR18 crores, funded through internal accruals and working capital limits (Page 8).
- No significant new capex required for current business models as enough funding has already been pumped into the CAMS model (Page 8).
- The hospital division expansion will be funded from the company’s own working capital; no external funding needed at this moment (Page 8).
- Plans for manufacturing point-of-care products and enhancing marketing and distribution are in pipeline, indicating potential future investments, though nothing concrete yet besides Saarthi (Page 13).
- Preferential allotment fundraise was announced but not yet closed; current acquisition executed without those funds (Page 8).
Track QMS Medical — get its next earnings analysis in your feed
How does QMS Medical rank vs peers in Healthcare Equipment & Supplies?
Pro featureHow does QMS Medical rank in Healthcare Equipment & Supplies?
Compare QMS Medical against every Healthcare Equipment & Supplies company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What QMS Medical's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Fischer Medical (Q2 FY27)
For the quarter ended September 30, 2026, the Standalone revenue from operations was ₹27.62 Lakhs compared to ₹742.69 Lakhs in Q2 FY 2025, showing a…
- Mohini Health (Q2 FY27)
Revenue from operations for the half year ended 30th Sept 2026 is ₹11,043.00 lakhs, compared to ₹7,353.87 lakhs for the half year ended 30th Sept 2025, showing…
- Aprameya Enginee (Q2 FY27)
216.21 lakhs, up 97% year-on-year (YoY). Key results statement takeaways from Aprameya Engineering Ltd's Q2 FY27 results statement — and how it ranks against se
- OSEL Devices (Q2 FY27)
Revenue from operations for H1 FY27: ₹193.6 Cr, up 31.8% YoY from ₹146.9 Cr in H1 FY26 (Page 4, 20). Key investor presentation takeaways from OSEL Devices Ltd's